EUVIMEDEUVIMED entdecken
Crossref

In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs

Marie H Deventer iD, Mattias Persson iD, Caitlyn Norman iD, Huiling Liu iD, Matthew J Connolly iD, Niamh Nic Daéid iD, Craig McKenzie iD, Henrik Gréen iD, Christophe P Stove iD

Drug Testing and Analysis · 2024

DOI: 10.1002/dta.3592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2024. Verfasst von Marie H Deventer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Cannabinoid Receptor Agonists, Cannabinoids, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: The Eurostars-2 Joint Programme (European Commission, E! 113377, Eurostars-2), Research Foundation Flanders (FWO), Eurostars-2 Joint Programme (European Commission, E! 113377, Eurostars-2).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following the enactment of a generic ban in China in 2021, the synthetic cannabinoid market has been evolving, now encompassing even wider structural diversity. Compounds carrying a brominated core such as ADB‐5′Br‐BUTINACA (ADMB‐B‐5Br‐INACA) and tail‐less analogs, such as ADB‐5′Br‐INACA (ADMB‐5Br‐INACA), MDMB‐5′Br‐INACA, and ADB‐INACA (ADMB‐INACA), have been detected since late 2021. This study investigated the cannabinoid receptor (CB) activation potential of synthesized ( S )‐enantiomers of these substances, as well as of two predicted analogs MDMB‐5′Br‐BUTINACA (MDMB‐B‐5Br‐INACA) and ADB‐5′F‐BUTINACA (ADMB‐B‐5F‐INACA), using CB 1 and CB 2 β‐arrestin 2 recruitment assays and a CB 1 intracellular calcium release assay. Surprisingly, the tail‐less ( S )‐ADB‐5′Br‐INACA and ( S )‐MDMB‐5′Br‐INACA retained CB activity, albeit with a decreased potency compared to their tailed counterparts ( S )‐ADB‐5′Br‐BUTINACA and ( S )‐MDMB‐5′Br‐BUTINACA, respectively, which were potent and efficacious CB 1 agonists. Also, at CB 2 , tail‐less analogs showed a lower potency but increased efficacy. Removing the bromine substitution (( S )‐ADB‐INACA) resulted in a reduced activity at CB 1 ; however, this effect was less prominent at CB 2 . Looking at tailed analogs, replacing the bromine with a fluorine substitution (( S )‐ADB‐5′F‐BUTINACA) resulted in an increased potency and efficacy at both receptors. Furthermore, as ADB‐5′Br‐INACA and MDMB‐5′Br‐INACA have been frequently detected together in Scottish prisons, this study also evaluated the CB 1 receptor activation potential of different mixtures of their respective reference standards, showing no unexpected cannabimimetic effect of combining both substances. Lastly, two powders seized by Belgian Customs and confirmed to contain ADB‐5′Br‐INACA and MDMB‐5′Br‐INACA, respectively, were assessed for CB activity. Based on the comparison with their reference standards, varying degrees of purity were suspected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cannabinoid Receptor AgonistsCannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2HumansHalogenationAnimalsHEK293 CellsCricetulusChinaCHO Cells

Stichwörter der Autor:innen

ADB‐5Br‐BUTINACAADB‐5Br‐INACACB1 cannabinoid receptorMDMB‐5Br‐INACAbrominated synthetic cannabinoid receptor agonists

Substanzen

Cannabinoid Receptor AgonistsCannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Autor:innen und Institutionen

  • Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden.
  • Leverhulme Research Centre for Forensic Science, School of Science and Engineering, University of Dundee, Dundee, UK.
  • Chiron AS, Trondheim, Norway.
  • Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

ORCID-Profile: Marie H Deventer, Mattias Persson, Caitlyn Norman, Huiling Liu, Matthew J Connolly, Niamh Nic Daéid, Craig McKenzie, Henrik Gréen, Christophe P Stove

Förderung

  • The Eurostars-2 Joint Programme (European Commission, E! 113377, Eurostars-2)
  • Research Foundation Flanders (FWO)
  • Eurostars-2 Joint Programme (European Commission, E! 113377, Eurostars-2)
  • Strategic Research Area in Forensic Sciences (Linköping University)
  • Leverhulme Trust
  • Scottish Prison Service
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Deventer, M. H., Persson, M., Norman, C., Liu, H., Connolly, M. J., Daéid, N. N., McKenzie, C., Gréen, H., & Stove, C. P. (2024). In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs. Drug Testing and Analysis. https://doi.org/10.1002/dta.3592

Vancouver

Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, et al. In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs. Drug Testing and Analysis. 2024. doi:10.1002/dta.3592

BibTeX
@article{Deventer2024,
  author = {Deventer, Marie H and Persson, Mattias and Norman, Caitlyn and Liu, Huiling and Connolly, Matthew J and Daéid, Niamh Nic and McKenzie, Craig and Gréen, Henrik and Stove, Christophe P},
  title = {In vitro cannabinoid activity profiling of generic ban‐evading brominated synthetic cannabinoid receptor agonists and their analogs},
  journal = {Drug Testing and Analysis},
  year = {2024},
  doi = {10.1002/dta.3592}
}
Kostenlos starten →